Retatrutide – 3 Pack (BAC Included)

Name: Retatrutide – 3 Pack (BAC Included)
Availability: InStock

$160.00

Retatrutide – 3 Pack typically refers to a bundle of three vials of Retatrutide, a potent “triple agonist” peptide currently in Phase III clinical trials. While developed by Eli Lilly as a next-generation treatment for obesity and type 2 diabetes,

Category: Buy PEPTIDES Tags: is peptide sciences legit, k18 peptide prep ph maintenance shampoo, kate farms pediatric peptide, kiss peptide, lvlup peptides, medicube pdrn pink peptide serum ingredients, micro ingredients multi collagen peptides

Description
Reviews (0)

Buy Retatrutide – 3 Pack

Retatrutide – 3 Pack FOfor sale USA typically refers to a bundle of three vials of Retatrutide, a potent “triple agonist” peptide currently in Phase III clinical trials. While developed by Eli Lilly as a next-generation treatment for obesity and type 2 diabetes, multi-vial packs sold online are usually marketed as unregulated research peptides and are not approved for human consumption.

Core Mechanism: The “Triple G” Action

Retatrutide is uniquely engineered to activate three different hormone receptors simultaneously, giving it superior efficacy over earlier dual-agonists like Tirzepatide:

GLP-1: Reduces appetite and slows gastric emptying to help users feel fuller longer.
GIP: Enhances insulin secretion and plays a key role in improving fat metabolism.
Glucagon: Increases energy expenditure (calorie burning) and directly promotes the breakdown of fat cells for energy.

2026 Clinical and Research Landscape

Weight Loss Efficacy: Phase III clinical trial data (TRIUMPH-4) released in late 2025 showed that Retatrutide produced an average weight loss of up to 28.7% (nearly 71 lbs) over 68 weeks.
- Expanded Indications: Beyond obesity, researchers are studying its effects on metabolic dysfunction-associated steatotic liver disease (MASH), chronic kidney disease, and knee osteoarthritis pain.
- Approval Status: As of January 2026, Retatrutide is not FDA-approved. Phase III trials are expected to conclude in May 2026, with potential regulatory approval and market launch anticipated for late 2026 or 2027.
Dosing and Handling (Research Context)

In research settings, a “3 Pack” is often used to accommodate the standard titration protocol:
- Titration: Subjects typically begin on a low dose (e.g., 2 mg) which is increased every four weeks until reaching a maintenance dose of 4 mg, 9 mg, or 12 mg.
- Reconstitution: Vials are typically 10mg or 15mg of lyophilized powder, requiring Bacteriostatic Water for injection.
- Storage: Reconstituted vials must be kept refrigerated at 2°C–8°C to maintain stability. Safety Warning: Retatrutide is currently a prohibited substance in competitive sports by the World Anti-Doping Agency (WADA). Accessing it outside of a registered clinical trial is considered illegal and unsafe, as unregulated products lack guaranteed purity and safety oversight.